RxDoctor Payments Data

Mayowa Ogunfowokan, APRN

Nurse Practitioner · Riverside, ILNPI 1063046092

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $14,250 of the $22,448 with a category attached, or 63.5%. ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) accounts for 69.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $12,627 and has fallen 89.6% since, to $1,313 in 2025. Among nurse practitioner clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$22,448in general payments, 2019–2025

Across 166 payments — averaging $135.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$16K
  • Boston Scientific$5K
  • Edwards Lifesciences$1K
  • E.r. Squibb & Sons, L.L.C.$345
  • Medtronic$248
  • Kestra Medical Technology Services, Inc.$127
  • plus $185 from 3 others

What the payments were for

  • Speaking & faculty fees$14,25063%
  • Travel & lodging$1,2886%
  • Food & beverage$6,91031%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,448 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$26,933
Medicare patients
190
Services billed
480

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban479$630,040
XareltoRivaroxaban128$179,094
MultaqDronedarone Hcl61$103,859
Dofetilide97$20,468
Metoprolol Succinate663$12,741
Flecainide Acetate199$8,347
Amiodarone Hcl229$8,222
Mexiletine Hcl21$2,707
Diltiazem 24hr Er (Cd)Diltiazem Hcl67$2,122
Midodrine Hcl19$1,067
SotalolSotalol Hcl58$920
Colchicine56$881
Sucralfate65$703
Metoprolol Tartrate85$698
Pantoprazole Sodium74$646

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$76$630,040479 claims
Johnson & JohnsonXarelto$65$179,094128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Riverside

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →